Methadone treatment for pain states

American Family Physician

Volumn 71, Issue 7, 2005, Pages 1353-1358

  Toombs, James D ^a,b   Kral, Lee A ^a,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUTORPHANOL TARTRATE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DELAVIRDINE; DEZOCINE; DIAZEPAM; FENTANYL; FLUCONAZOLE; FLUOXETINE; GLYCOPROTEIN P; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; KETOCONAZOLE; METHADONE; MORPHINE SULFATE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALBUPHINE; NALORPHINE; NORADRENALIN; OMEPRAZOLE; OPIATE; OXYCODONE; PAROXETINE; PENTAZOCINE; QUINIDINE; SEROTONIN; UNINDEXED DRUG; VERAPAMIL;

ANALGESIA; CANCER PAIN; CHRONIC PAIN; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERANCE; GENERAL PRACTITIONER; HUMAN; NEUROPATHIC PAIN; PAIN; PATIENT MONITORING; PRESCRIPTION; RESPIRATION DEPRESSION; REVIEW;

ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG COSTS; DRUG INTERACTIONS; HUMANS; METHADONE; PAIN; THERAPEUTIC EQUIVALENCY;

EID: 16844369412     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Chen KK. Pharmacology of methadone and related compounds. Ann N Y Acad Sci 1948;51:83-4.
2. Methadone listing as new drug with special requirements and opportunity for hearing. Federal Register 1972;37(242):26790-807. Accessed online November 10, 2004, at: http://www.nida.nih.gov/pdf/monographs/OS.pdf.
3. Restrictions on distribution of methadone. Federal Register 1976;41(135):28261-4. Accessed online November 10, 2004, at: http://www.nida.nih.gov/pdf/monographs/08.pdf.
4. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986;25:297-312.
5. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999;42:61-6.
6. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-93.
7. Mercadante S, Sapio M, Serretta R, Caligara M. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Ann Oncol 1996;7:613-7.
8. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
9. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000;16(2 suppl):S73-9.
10. Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth Analg 2004;98:653-9.
11. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14:2836-42.
12. Gardner-Nix JS. Oral methadone for managing chronic nonmalignant pain. J Pain Symptom Manage 1996;11:321-8.
13. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2004;(2):CD003971.
14. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19:2898-904.
15. Evidence-based recommendations for medical management of chronic non-malignant pain: reference guide for physicians. The College of Physicians and Surgeons of Ontario. November 2000. Accessed online November 10, 2004, at: http://www.cpso.on.ca/Publications/pain.htm.
16. Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 1998;5:51-8. Accessed online November 10, 2004, at: http://www.globalrph.com/narcoticonv.htm.
17. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;20:348-52.
18. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th ed. Glenview, Ill.: American Pain Society, 2003:16.
19. Ripamonti C, De Conno F, Groff L, Belzile M, Pereira J, Hanson J, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998;9:79-83.
20. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998;16:3216-21.
21. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672-87.
22. Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust 2000;173:536-40.
23. Shir Y, Rosen G, Zeldin A, Davidson EM. Methadone is safe for treating hospitalized patients with severe pain. Can J Anesth 2001;48:1109-13.
24. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002;5:127-38.
25. Mercadante S, Casuccio A, Agnello A, Barresi L. Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999;18:188-92.
26. De Castro J, Aguirre C, Rodriguez-Sasiain JM, Gomez E, Garrido MJ, Calvo R. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharm Drug Dispos 1996;17:551-63.
27. Bouer R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 1999;13:494-500.
28. Tatro DS. Drug interaction facts: the authority on drug interactions. St. Louis, Mo.: Facts and Comparisons, 2005:490-3.
29. Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999;18:369-75.
30. Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993-99. Aust N Z J Public Health 2002;26:364-70.
31. 2004 Drug topics red book: the pharmacist's trusted companion for more than a century. Montvale, N.J.: Medical Economics, 2004.